ArticleACS materials letters2026
A Structurally Dynamic Pathogen-Mimicking Biomaterial Is an Efficient Activator of Dendritic Cells.
Article in ACS materials letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Structural dynamism confers intriguing applications to biocompatible materials. Here, we present a protein-based, self-organizing microscale material designed to mimic pathogen-like features. In this formulation, the building block proteins shift their organization through monomeric, microscale, or oligomeric nanoscale states, which is expected to enhance antigen uptake and immune activation. To validate the system, several CT26-derived tumor neoantigens, namely, Ubqln1, AHSL and Phf3, have been assembled as mixed granules, leaking nanoscale protein oligomers. When challenging dendritic cells, this formulation enhanced the expression of the activation markers CD40 and MHC II compared with soluble antigens, underscoring the material's ability to potentiate antigen-presenting functions. While many antigens are attractive targets due to their unique expression in malignant cells, their poor immunogenicity in soluble versions may render them ineffective. The present approach represents a transversal and feasible tool to enhance the immunogenicity of protein antigens through a dynamic material platform that expands their translational potential.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.